The efficacy of dupilumab in the treatment of severe allergic asthma and CRS and studies in STAT6-deficient mice highlight the central role of the IL4/IL13-IL4Rα-STAT6 signaling pathway in developing eosinophilic asthma (8–10). The gene discussed is STAT6; the disease is congenital rubella syndrome.